Kupkina A. Features of the clinical course and optimization of treatment of bronchial asthma in children with overweight and obesity.

This dissertation is devoted to the study of the features of clinical course and optimization of the treatment of bronchial asthma in children with concomitant overweight and obesity. According to WHO 2020 estimations, bronchial asthma is the most common chronic pathology in the world among children. According to official statistics published in the WHO Global Asthma Report 2018, the prevalence of bronchial asthma in the region uniting Western and Eastern Europe (which includes Ukraine), among children aged 6-7 years is 8,7 %, among children aged 13-14 years is 9,7 %. One of the concomitant pathologies that can aggravate the course of bronchial asthma is overweight and obesity, which have also spread rapidly in recent decades. According to UNICEF estimates in 2019, in Eastern Europe almost 1 in 7 children under 5 years of age are overweight, and the trend of obesity in the world suggests that by 2025 the number of overweight children under 5 years of age will increase to 43 millions. The problem of the comorbid course of bronchial asthma and obesity has already attracted the attention of scientists around the world, because modern recommendations are usually aimed at providing assistance for each of the nosologies separately, without taking into account the aggravating effects of both diseases. Objectives of the research: 1. To study the pecularities of the clinical course of bronchial asthma in children with overweight and obesity. 2. To investigate the lung function in children with asthma, who are overweight and obese. 3. To determine the changes in inflammation markers due to minimal chronic persistent inflammation in children with asthma, who are overweight and obese. 4. То assess the quality of life of children with asthma, who are overweight and obese. 5. To justify the choice of control therapy for bronchial asthma in overweight and obese children using a combination of low doses of inhaled glucocorticosteroids with the antileukotriene drug montelukast, taking into account the phenotype of the disease.